Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2021 / Cilt: 55 - Sayı: 4

Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity

Sayfa
[545]–550
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The most important risk factor for myopia and anisometropia in premature children may be ROP severity and retinal immaturity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The purpose of the study was to evaluate the effect of different treatment modalities on refractive outcomes in patients treated with severe retinopathy of prematurity (ROP).
📊
Temel Bulgular & Veri:Methods: The records of children who were treated for severe ROP in our clinic between January 2015 and August 2018 were retrospectively reviewed.
💡
Sonuç & Katkı:The most important risk factor for myopia and anisometropia in premature children may be ROP severity and retinal immaturity.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: The purpose of the study was to evaluate the effect of different treatment modalities on refractive outcomes in patients treated with severe retinopathy of prematurity (ROP). Methods: The records of children who were treated for severe ROP in our clinic between January 2015 and August 2018 were retrospectively reviewed. The children who were treated were analyzed in three subgroups as intravitreal bevacizumab (IVB), laser photocoagulation (LPC), and IVB + LPC. Spherical equivalent (SEQ), spherical and cylindrical power measurements of the cases were recorded in diopters (D). SE ≤−0.25D was accepted as myopia and SE of more than 1 D between two eyes was accepted as anisometropia. Results: A total of 160 eyes of 80 participants were eligible for inclusion: 38 eyes in the IVB group, 24 eyes in the LPC group, 16 eyes in the IVB + LPC group, 44 eyes in the spontaneously regressed group, and 38 eyes in the full-term children. Although the mean spherical power and SEQ in the IVB group were lower than in the LPC group (p=0.019 and 0.013, respectively), there was no significant difference between the IVB group and the IVB + LPC group (p=0.541 and 0.804, respectively). In terms of mean cylindrical power and prevalence of myopia and anisometropia, there was no significant difference between the treatment groups (p>0.05). Conclusion: Although spherical power and SEQ can change according to the ROP treatment management, there is no difference in terms of the cylindrical power, prevalence of myopia, and anisometropia. The most important risk factor for myopia and anisometropia in premature children may be ROP severity and retinal immaturity.

🔖

Bu Makaleye Atıf Yap

DEMİR, S. T., YESİLTAS, S. K., KARAPAPAK, M., OZYUREK, E. B. A., BÜLBÜL, A., USLU, H. S., GÜVEN, D. (2021). Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 55 - Sayı: 4, [545]–550. https://ajindex.com/articles/402844

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Terry TL. Extreme prematurty and fibroblastic overgrowth of persistant vascular sheat behind each crystalline lens. Am J Ophtalmol 1942;25:203–4
  2. Mutlu FM, Sarici SU. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 2013;6:228–36
  3. Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol 2018;18:19
  4. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ reti nopathy of prematurity. N Engl J Med 2011;364:603–15
  5. Hsieh CJ, Liu JW, Huang JS, Lin KC. Refractive outcome of premature infants with or without retinopathy of prematurity at 2 years of age: a prospective controlled cohort study. Kaohsiung J Med Sci 2012;28:204–11
  6. Holmström GE, Larsson EK. Development of spherical equivalent refraction in prematurely born children during the first 10 years of life: a population-based study. Arch Ophthalmol 2005;123:1404– 11
  7. Gursoy H, Basmak H, Bilgin B, Erol N, Colak E. The effects of mildto- severe retinopathy of prematurity on the development of refractive errors and strabismus. Strabismus 2014;22:68–73
  8. Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al; BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014;132:1327–33
  9. Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 2017;101:365–70
  10. Tiryaki Demir S, Karapapak M, Uslu HS, Bulbul A, Guven D, Dirim AB, et al. Retinopathy screening results of late-preterm infants born at 32-35 weeks of gestational age. Graefes Arch Clin Exp Ophthalmol 2019;257:1325–9
  11. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572–6
  12. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991–9. 13.